Menu

NIH Expands Undiagnosed Diseases Program

The National Institutes of Health is funding six extramural medical centers to help identify the causes of mysterious diseases.

Jul 3, 2014
Tracy Vence

FLICKR, RVOEGTLIThe National Institutes of Health (NIH) is giving six additional medical centers a total of $43 million to take part in its Undiagnosed Diseases Network, through which the agency is supporting research to unravel the causes of prolonged, mysterious conditions. The network is an extramural expansion of the agency’s Undiagnosed Diseases Program, which is headquartered at the Clinical Center on the NIH campus in Bethesda, Maryland.

Investigators from the Baylor College of Medicine, Boston Children’s Hospital, Duke University, Stanford University, the University of California, Los Angeles, and the Vanderbilt University Medical Center will now take part in a program that’s using genomic and other approaches, to ascertain the causes of rare, idiopathic conditions.

“We believe that there is a substantial unmet demand for the diagnoses of conditions that have perplexed skillful physicians,” grant recipient Isaac Kohane, a professor of pediatrics at Harvard Medical School and Boston Children’s Hospital, said in an NIH statement. “We want to address inquiries from physicians and patients throughout the country who require these services and, in doing so, create a 21st century model for diagnosis and treatment in this genomic and information-intensive era.”

July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 Software
DNASTAR® announced the release of Lasergene 16 today, which includes a broad range of improvements in for analysis of DNA, RNA and protein sequence data, as well as new advancements for predicting and analyzing protein structures. 
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences Partners with Curio Genomics for Analysis of IWGSC Wheat Exome
Arbor Biosciences, a division of Chiral Technologies, Inc and worldwide leader in next generation sequencing (NGS) target enrichment, announces a partnership with Curio Genomics for bioinformatics analysis of the wheat genome.
IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.